Franklin Genomic Advancements ETF (HELX)

Assets	$29.10M
Expense Ratio	0.50%
PE Ratio	33.05
Shares Out	750,000
Dividend (ttm)	$0.14
Dividend Yield	0.36%
Ex-Dividend Date	Dec 30, 2025
Payout Frequency	n/a
Payout Ratio	12.06%

Volume	1,529
Open	40.19
Previous Close	39.30
Day's Range	39.99 - 40.20
52-Week Low	27.54
52-Week High	41.30
Beta	0.97
Holdings	70
Inception Date	Feb 25, 2020

About HELX

Fund Home Page

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is issued by Franklin Templeton.

• Asset Class: Equity
• Category: Health
• Region: Global
• Stock Exchange: BATS
• Ticker Symbol: HELX
• ETF Provider: Franklin Templeton

Top 10 Holdings

47.70% of assets

Name	Symbol	Weight
Guardant Health, Inc.	GH	9.29%
Natera, Inc.	NTRA	7.46%
Krystal Biotech, Inc.	KRYS	6.28%
Adaptive Biotechnologies Corporation	ADPT	4.52%
Ligand Pharmaceuticals Incorporated	LGND	4.36%
BridgeBio Pharma, Inc.	BBIO	3.88%
United Therapeutics Corporation	UTHR	3.42%
Corteva, Inc.	CTVA	2.94%
Eli Lilly and Company	LLY	2.86%
Samsung Biologics Co.,Ltd.	207940	2.68%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 30, 2025	$0.14334	Jan 8, 2026
Dec 30, 2021	$0.00394	Jan 7, 2022
Dec 13, 2021	$0.11415	Dec 21, 2021
Dec 14, 2020	$0.05178	Dec 23, 2020

Performance

HELX had a total return of 42.95% in the past year, including dividends. Since the fund's inception, the average annual return has been 8.33%.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP. Several fund data points are also provided by Finnhub.

Last checked:

Aug 6, 2026

Data Sources Report a data error